Your Cart

Investor Hub

Imagion Biosystems (ASX:IBX) is backed by committed investors with a strong belief in our mission to find and eliminate cancer through early detection.

ASX Announcement Hub

NEW! Engage with us directly by asking questions, watching video summaries, and be part of the community.

Offer Booklet

Download a copy of our latest Non-renounceable Entitlement Offer Booklet

Technology Update

Catch up on our latest technology update and company focus announcement including FAQs

We are a clinical stage medical imaging company developing next generation molecular imaging technologies to change the way we look at cancer.

Imagion Biosystems’ innovative medical imaging technology uses bio-safe magnetic nanoparticles to detect cancer and other diseases.

Our proprietary MagSense® technology is non-invasive and non-radioactive, providing more specific and accurate detection of cancer than current imaging technologies. And we have multiple commercial opportunities with magnetic nanoparticles including our proprietary MagSense® imaging technology, MRI contrast agents and therapy/drug delivery.

Investment Highlights

Listed on the ASX: June 2017
R&D operations: San Diego
Registered office: Melbourne

A Clinical Stage Medical Device Company developing bio-safe medical imaging technologies

  • Multi-faceted imaging technology using magnetic nanoparticles coated with a targeting antibody to detect cancer tumors
  • Multiple commercial possibilities and targeting a printer-ink revenue model in addition to other opportunities

Addressing large markets and unmet needs in earlier more specific detection of cancers

  • One in three people impacted by cancer
  • Over $100B spent annual in cancer diagnosis but still unable to noninvasively diagnosis tumors
  • Current medical imaging technologies invented more than 50 years ago

MagSense® technology will transform cancer diagnosis

  • Does not require radioactivity
  • Uses bio-safe magnetic nanoparticles
  • Designated as a ‘breakthrough device’ by the FDA

Multiple revenue opportunities

  • High gross margin proprietary molecular imaging agents
  • Ability to extend utility to therapeutic applications
  • Supply agreements with 3rd parties for use in their medical products

Strong leadership and advisory board

  • Experienced and skill diverse board of directors and management team
  • Scientific advisory board with collective expertise in oncology, medical imaging, nanotechnology and clinical trial design

IBX Share Price History

Investment Quick Links

Latest News

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Investor Services

Investors seeking information regarding their shareholding or dividends or wishing to advise of a change of address should contact Boardroom Pty Limited at:

Boardroom Pty Limited
Level 12, 225 George Street,
Sydney, NSW, 2000
Telephone: (02) 9290 9600 Facsimile: (02) 9279 0664 or
Visit the online service at

Boardroom Pty Limited has an online service for investors called InvestorServe. This enables investors to make online changes, view balances and transaction history, as well as obtain information about recent dividend payments and download various forms to assist in the management of their holding.

To request listed option conversion forms, please email Boardroom at:

Questions? Reach the Investor Relations department: